Enzon Pharmaceuticals, Inc.

Sector: Pharmaceutical Preparations Region: NJ, United States

Exchange/Ticker: Nasdaq: ENZN

Company Description

Enzon Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the research and development of innovative therapeutics for cancer patients with high unmet medical needs. Its drug-development programs utilize two platforms such as customized PEGylation linker technology and third-generation mRNA-targeting agents utilizing the locked nucleic acid technology. The company currently has four compounds in human clinical development and multiple novel locked nucleic acid targets in preclinical research. It develops, manufactures and markets pharmaceutical products for patients with cancer and other life-threatening diseases in the United States and Europe. The company markets four human therapeutic products: Abelcet, Oncaspar, Adagen and Depocyt. ABELCET is a lipid complex formulation of amphotericin B used primarily in the hospital to treat immuno-compromised patients with invasive fungal infections. ONCASPAR is a PEG-enhanced version of a naturally occurring enzyme called L-asparaginase. ADAGEN is used to treat patients afflicted with a type of severe combined immunodeficiency disease, also known as the 'Bubble Boy' disease, which is caused by the chronic deficiency of the adenosine deaminase enzyme. DEPOCYT is an injectable chemotherapeutic approved for the treatment of patients with lymphomatous meningitis. Enzon Pharmaceuticals was founded by Abraham Abuchowski in 1981 and is headquartered in Piscataway, NJ.

Similar to: ViroPharma, Inc., Skystar Bio-Pharmaceutical Co., GW Pharmaceuticals Plc

Featured Company

Fidelity Asian Values Plc

Tadworth, SU, GB

Fidelity Asian Values Plc is a Closed-End Investment Fund/Investment. The company invests in information technology, energy, financial… Learn more →